CARLSBAD, Calif., Feb. 12 /PRNewswire-FirstCall/ -- Ardea Biosciences,
Inc. (Nasdaq: RDEA) today announced that Barry D. Quart, PharmD, President
and CEO of Ardea Biosciences, will present at the Roth Capital Partners'
20th Annual OC Growth Stock Conference.
Date: Tuesday, February 19, 2008
Time: 4:00 p.m. Pacific Time
Location: The Ritz Carlton Laguna Niguel, Dana Point, CA
Webcast: http://www.wsw.com/webcast/roth16/rdea/ or
About Ardea Biosciences, Inc.
Ardea Biosciences of Carlsbad, California is a biotechnology company focused on the discovery and development of small-molecule therapeutics in virology, oncology and inflammation. The Company has two product candidates in clinical development and several others in preclinical development. Ardea's most advanced clinical development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. In addition, the Company is also investigating RDEA806 for the treatment of gout. In oncology, the Company is investigating a mitogen-activated ERK kinase (MEK) inhibitor, RDEA119, in a Phase 1 study in advanced cancer patients. Ardea also is developing a next-generation NNRTI for HIV and a next-generation MEK inhibitor for both cancer and inflammatory diseases.
Statements contained in this press release regarding matters that are
not historical facts are "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, ac
|SOURCE Ardea Biosciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved